Effects of Spirulina platensis supplementation on lipid profile in HIV-infected antiretroviral naïve patients in Yaounde - Cameroon: A randomized trial study

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Ngo Matip, Marthe Elise ^a   Pieme, Constant Anatole ^b   Azabji Kenfack, Marcel ^b   Biapa, Prosper Cabral Nya ^c   Germaine, Nkenfack ^c   Heike, Englert ^d   Moukette, Bruno Moukette ^b   Emmanuel, Korosky ^e   Philippe, Stefanini ^f   Mbofung, Carl Moses ^a   Ngogang, Jeanne Yonkeu ^b  

^a UNIVERSITY OF NGAOUNDERE   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF DSCHANG   (Cameroon)

^e Spirulina Producer's Federation of France   (France)

^f Ecole de Formation Agricole de Hyères   (France)

Author keywords

Atherosclerosis; HIV+ antiretroviral na ve; Lipid profile; Spirulina platensis

Indexed keywords

CD4 ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ANALYTICAL PARAMETERS; ARTHROSPIRA PLATENSIS; ARTICLE; ATHEROGENIC INDEX; BODY MASS; BODY WEIGHT; CAMEROON; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOOD INTAKE; FOOD QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; MACRONUTRIENT; MAJOR CLINICAL STUDY; MALE; MINERAL INTAKE; MULTICENTER STUDY; NUTRITIONAL ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TOTAL CHOLESTEROL TO HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO; TOTAL CHOLESTEROL TO LOW DENSITY LIPOPROTEIN CHOLESTEROL RATIO; BLOOD; CLINICAL TRIAL; DIETARY SUPPLEMENT; DYSLIPIDEMIAS; LONGITUDINAL STUDY; MIDDLE AGED; SPIRULINA; TREATMENT OUTCOME;

ADULT; CAMEROON; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SPIRULINA; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84976905718     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-191     Document Type: Article

References (55)

1. Triant VA: HIV infection and coronary heart disease: an intersection of epidemics. J Infec Dis. 2012, 205: 355-361. 10.1093/infdis/jir753.
2. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC,: Study Prevalence of risk factors for cardiovascular disease in HIVinfected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006, 7: 404-410. 10.1111/j.1468-1293.2006.00400.x
3. Palella FJ, Baker RK, Moorman AC, Chmie JS, Wood KC, Brooks JT, Holmberg SD,: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006, 43: 27-34. 10.1097/01.qai.0000233310.90484.16
4. Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endo Crinol Metab. 2007, 92: 2506-2512. 10.1210/jc.2006-2190.
5. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, Morlat P, Salmon D, Cacoub P, Chêne G,: Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008, 48: 590-598. 10.1097/QAI.0b013e31817efb54
6. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, Capeau J, Cohen A: HIV and coronary heart disease time for a better understanding. J Am Coll Card. 2013, 61 (5): 511-523. 10.1016/j.jacc.2012.06.063.
7. UNAIDS/WHO. AIDS Epidemic Update, Volume 232. 2009, 196-197.
8. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS: Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naïve cohort. HIV Med. 2005, 6: 114-121. 10.1111/j.1468-1293.2005.00273.x
9. Albuquerque Gonçalves VM, Zírpoli JC, de Barros MF D, Albuquerque Mde F, Ulisses RM, de Alencar Ximenes RA, Lacerda HR: Risk factors for subclinical atherosclerosis in HIV-infected patients under and over 40 years: a case-control study. BMC Infec Dis. 2013, 13: 214-10.1186/1471-2334-13-214.
10. Mbanya JC, Minkoulou E, Salah J, Balkau B: The Prevalence of Hypertension in Rural and Urban Cameroon. Int J Epidemiol. 1998, 27 (2): 181-185. 10.1093/ije/27.2.181
11. Mbewu A, Mbanya JC: Cardiovascular Disease In Disease and Mortality in Sub-Saharan Africa. 2006, 1-36. 2
12. Tantchou Tchoumi JC, Butera G: Profile of cardiac disease in Cameroon and impact on health care services. Cardiovasc Diagn Ther. 2013, 3 (4): 236-243.
13. Magula NP, Mayosi BM: Cardiac involvement in HIV-infected people living in Africa: a review. Cardiovasc J S Afr. 2003, 14: 231-237.
14. Preliminary Results of the Demographic and Health Survey (DHS-III). 2004, Yaounde- Cameroon: Ministry of Public Health
15. HUANG PL: A comprehensive definition for metabolic syndrome. Dis Models Mech. 2009, 2: 231-237. 10.1242/dmm.001180.
16. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT: Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005, 39 (2): 199-202.
17. Semenkovich CF: Insulin resistance and atherosclerosis. J Clin Invest. 2006, 116: 1813-1822. 10.1172/JCI29024
18. Grinspoon SMD, Carr Andrew MD: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New Engl J Med. 2005, 352: 48-62. 10.1056/NEJMra041811
19. Ramezani A, Mohraz M, Banifazl M, Gachkar L, Jam S, Eslamifar A, Yaghmaie F, Nemati K, Aghakhani A: Metabolic abnormalities in HIV-positive patients receiving highly active antiretroviral therapy. Iranian J Path. 2007, 2 (3): 154-158.
20. Madhu N, Rao MN, Lee GA, Grunfeld C: Metabolic abnormalities associated with the use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors. Am J Infect Dis. 2006, 2 (3): 159-166. 10.3844/ajidsp.2006.159.166
21. Currier JS: Update on cardiovascular complications in HIV infection. Los Angeles USA HIV-MED. 2009, 17: 98-103.
22. Almeida LB, Degurado AC, Duran AC, Jaime PC: Impact of a nutritional counseling program on prevention of HAART-related metabolic and morphologic abnormalities. AIDS Care. 2011, 6 (23): 755-763.
23. Botros D, Somarriba G, Neri D, Miller Tracie L: Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals. Curr HIV/AIDS Rep. 2012, 9 (4): 351-363. 10.1007/s11904-012-0135-7.
24. Azabji-Kenfack M, Loni GE, Sobngwi E, Onana EA, Dikosso ES, Von der Weid D, Gbaguidi E, Ngogang J, Mbanya JC: The effect of Spirulina Platensis versus soybean on insulin resistance in HIV-infected patients: a randomized pilot study. Nutrients. 2011, 3: 712-724. 10.3390/nu3070712
25. Suelen Jorge S, Liania Alves L, Sigrid Sousa S, Carvalho RPH: Lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: A case-control study. HIV Med. 2010, 11: 353-359.
26. De Pee S, Semba RD: Role of nutrition in HIV infection: review of evidence for more effective programming in resource-limited settings. Food Nutr Bull. 2010, 31 (4): 313-344.
27. Lecerf J-M,: Les compléments alimentaires: intérêts et limites. 2008, http://www.institutdanone.org/comprendre/publications/objectif-nutrition/081/dossier.php
28. Leonard J, Compere P: Spirulina platensis (Gom.) Geitler, algue bleue de grande valeur alimentaire par sa richesse en proteines. Bull Nat Plantentuin Belg. 1967, 37 (1): 23-
29. Delpeuch F, Joseph A, Cavelier C: Consommation alimentaire et apport nutritionnel des algues bleues (Oscillatoris platensis) chez quelques populations du Kanem (Tchad). Anna Nutr Alim. 1975, 29: 497-515.
30. Colla LM, Muccillo-Baisch AL, Vieira Costa JA: Spirulina platensis effects on the levels of total cholesterol, HDL and triacylglycerols in rabbits fed with a hypercholesterolemic diet. Braz Arch Biol Technol. 2008, 51 (2): 405-411. 10.1590/S1516-89132008000200022.
31. Sun Hee C, Mi Yeon K, Dai-Eun S, Seock-Yeon H, Yin Hee K, Hye Ran K, Jeung Hee L, Jung-Bae K, Mee Ree K: Spirulina prevents Atherosclerosis by reducing Hypercholesterolemia in Rabbits Fed a High- Cholesterol Diet. J Nutr Sci Vitaminol. 2010, 56: 34-40. 10.3177/jnsv.56.34
32. Nagaoka S, Shimizu K, Kaneko H, Shibayama F, Morikawa K, Kanamaru Y, Otsuka A, Hirahashi T, Kato T: A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina Platensis concentrate in rats. J Nutr. 2005, 135: 2425-2430.
33. Romay C, Armesto J, Remirez D, Gonzalez R, Ledon N, Garcia I: Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflam Res. 1998, 47 (1): 36-41. 10.1007/s000110050256.
34. Official Methods of Analysis. 1990, 2-Washington, DC: Association of Official Analytical Chemist, 15
35. Recueil des Normes Françaises. Acides gras et composés lipidiques. 1981, 250-
36. Cerning J, Guilbot J: Change in carbohydrate composition during maturation of wheat and barley kernel. Cereal Chem. 1973, 50: 220-225.
37. Seth CK, Chauncey C, White D, Jones M, Moira OK, Mervi AD, Angela MC, Schinazi RF: Use of dietary supplements among people living with HIV/AIDS is associated with vulnerability to medical misinformation on the internet. AIDS Res Ther. 2012, 9: 1-doi:10.1186/1742-6405-9-1
38. Wolfram G: New reference values for nutrient intake in Germany, Austria and Switzerland (DACH-Reference Values). Forum Nut. 2003, 56: 95-97.
39. Friedewald WT, Levy RI, Frederickson DS: Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 449-502.
40. Using Dietary Supplements Wisely. 2014, http://nccam.nih.gov/sites/nccam.nih.gov/files/Using-Dietary-Supplements-Wisely-CAM-06-12-2014
41. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA: Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003, 289: 2978-2982. 10.1001/jama.289.22.2978
42. Nguemaïm NF, Mbuagbaw J, Nkoa T, Alemnji G, Této G, Fanhi TC, Asonganyi T, Samé-Ekobo A: Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: A case-control study. HIV Med. 2010, 11: 353-359.
43. Obirikorang C, Yeboah FA, Quaye L: Serum lipid profiling in highly active antiretroviral therapy-naive HIV positive patients in Ghana: Any potential risk?. Webmed Cent Infec Dis. 2010, 1 (10): 1-9.
44. Daniyam CA, Iroezindu MO: Lipid profile of anti-retroviral treatment-naïve HIV-infected patients in jos. Nigeria Ann Med Health Sci Res. 2013, 3 (1): 26-30. 10.4103/2141-9248.109468.
45. Lee JB, Srisomporn P, Hayashi K, Tanaka T, Sankawa U, Hayashi T: Effects of structural modification of calcium spirulan, a sulfated polysaccharide from Spirulina platensis, on antiviral activity. Chem Pharm Bull. 2001, 49 (1): 108-110. 10.1248/cpb.49.108
46. Iwata K, Inayama T, Kato T: Effects of Spirulina platensis on plasma lipoprotein Effects of Spirulina platensis on plasma lipoprotein lipase activity in fructose-induced hyperlipidemic rats. J Nutr Sci Vitaminol. 1990, 36 (2): 165-171. 10.3177/jnsv.36.165
47. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency Syndrome. J Clin Endocrinol Metab. 1992, 74: 1045-1052.
48. Lando G, Mbanya D, Magoue C: Lipid abnormalities in HIV/AIDS infected subjects in Cameroon. 2001, 89-[Abstract], Yaounde, Cameroon: 4th Congress of the Federation of African Societies of Biochemistry and Molecular Biology
49. Mc Donagh J, Fossel ET, Kradin RK, Dubinett SM, Laposata M, Hallaq YA: Effect of Tumor Necrosis Factor-a on peroxidation of plasma lipoprotein lipids in experimental animals and patients. Blood. 1992, 80: 3217-3226.
50. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, Simonoff M, Brossard G, Barbeau P, Fleury H: Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994, 24: 416-420. 10.1111/j.1365-2362.1994.tb02185.x
51. Cheong SH, Kim MY, Sok DE, Hwang SY, Kim JH, Kim HR, Lee JH, Kim YB, Kim MR: Spirulina prevents atherosclerosis by reducing hypercholesterolemia in rabbits fed a high-cholesterol diet. J Nutr Sci Vitaminol. 2010, 56: 34-40. 10.3177/jnsv.56.34
52. Leandro PM, Guilherme MP, Wladimir RB, Inaian PT, Ana Carolina G, Gláucio AS, Maria Alice RM: Exercise and spirulina control non-alcoholic hepatic steatosis and lipid profile in diabetic Wistar rats. Lipids Health Dis. 2011, 10: 77- 10.1186/1476-511X-10-77
53. Bhat VB, Madyastha KM: Scavenging of Peroxynitrite by Phycocyanin and Phycocyanobilin from Spirulina platensis: Protection against Oxidative Damage to DNA. Biochem BiophysRes Comm. 2001, 285: 262-266. 10.1006/bbrc.2001.5195.
54. Belay A: The potentiel application of Spirulina (Arthrospira) as a nutritional and therapeutic supplement in health management. J Am Nutraceut. 2002, 5 (2): 26-49.
55. Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ,: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003, 37: 613-627. 10.1086/378131